{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:03:06Z","timestamp":1782871386088,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ygyno.2024.10.010","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:06:26Z","timestamp":1729296386000},"page":"150-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis"],"prefix":"10.1016","volume":"191","author":[{"given":"Emanuele","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Capasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Trozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Congedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ervas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Guaita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"van Rompuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Franco","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.10.010_bb0005","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0020","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ajpath.2019.09.022","article-title":"Two distinct tumorigenic processes in endometrial endometrioid adenocarcinoma","volume":"190","author":"Sugiyama","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0030","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113317","article-title":"Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - an international pooled analysis of three ESGO accredited centres","volume":"193","author":"Schwameis","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2024.01.040","article-title":"2023 changes to FIGO endometrial cancer staging: counterpoint","volume":"184","author":"Leitao","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0060","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2021.10.071","article-title":"Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer","volume":"164","author":"Orellana","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.32074\/1591-951X-775","article-title":"Biomarker characterization in endometrial cancer in Italy: first survey data analysis","volume":"114","author":"Zannoni","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0070","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.ygyno.2021.03.031","article-title":"Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer","volume":"161","author":"Vrede","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0080","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2023.03.016","article-title":"Back to the future: the impact of oestrogen receptor profile in the era of molecular endometrial cancer classification","volume":"186","author":"Perrone","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0085","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2022.03.009","article-title":"The immunohistochemical molecular risk classification in endometrial cancer: a pragmatic and high-reproducibility method","volume":"165","author":"Perrone","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0090","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ygyno.2021.06.030","article-title":"Comprehensive immunomolecular profiling of endometrial carcinoma: a tertiary retrospective study","volume":"162","author":"Victoor","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0095","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0100","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.humpath.2020.12.003","article-title":"The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study","volume":"109","author":"van Weelden","year":"2021","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(24)00142-6","article-title":"Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials","volume":"25","author":"Wakkerman","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/ijgc-2023-004981","article-title":"FIGO 2023 endometrial cancer staging: too much, too soon?","volume":"34","author":"McCluggage","year":"2023","journal-title":"Int. J. Gynecol. Cancer."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2023.09.006","article-title":"Budget impact analysis of molecular subtype profiling in endometrial cancer","volume":"178","author":"Plotkin","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0130","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/ijgc-2022-003480","article-title":"A novel algorithm to implement the molecular classification according to the new ESGO\/ESTRO\/ESP 2020 guidelines for endometrial cancer","volume":"32","author":"Betella","year":"2022","journal-title":"Int. J. Gynecol. Cancer."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0140","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41379-022-01102-x","article-title":"p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial","volume":"35","author":"Vermij","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214318","article-title":"Phenotype of POLE-mutated endometrial cancer","volume":"14","author":"Imboden","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0150","doi-asserted-by":"crossref","first-page":"32","DOI":"10.32074\/1591-951X-926","article-title":"Biomarker characterization in endometrial cancer in Europe: first survey data analysis from 69 pathological academic and hospital labs","volume":"116","author":"Santoro","year":"2024","journal-title":"Pathologica"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0155","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0160","series-title":"Uterine Neoplasms (Version 2.2024-March 6, 2024)","author":"Network NCC","year":"2024"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","author":"Consortium RR","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14728222.2024.2316739","article-title":"New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere","volume":"28","author":"Bruchim","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ygyno.2024.10.010_bb0175","article-title":"Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0180","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer."},{"key":"10.1016\/j.ygyno.2024.10.010_bb0185","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ijgc-2023-004289","article-title":"Improving Endometrial cancer assessment by combining the new techniqUe of GENomic profiling with surgical Extra uterIne disEase assessment (EUGENIE)","volume":"33","author":"Kasius","year":"2023","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824011600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T01:52:52Z","timestamp":1733881972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824011600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"alternative-id":["S0090825824011600"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}